XML 125 R42.htm IDEA: XBRL DOCUMENT v3.20.4
Segmentation of key figures (Tables)
 12 Months Ended
Dec. 31, 2020
Statement [line items]  
Segmentation - Consolidated income statements
Segmentation – consolidated income statements
Innovative Medicines
Sandoz
Corporate (including eliminations)
Group
(USD millions)
2020
2019
2020
2019
2020
2019
2020
2019
Net sales to third parties from continuing operations
39 013
37 714
9 646
9 731
48 659
47 445
Sales to continuing and discontinued segments
792
783
189
141
– 981
– 871
53
Net sales from continuing operations
39 805
38 497
9 835
9 872
– 981
– 871
48 659
47 498
Other revenues
1 018
1 092
53
63
168
24
1 239
1 179
Cost of goods sold
– 10 927
– 10 050
– 5 252
– 5 334
1 058
959
– 15 121
– 14 425
Gross profit from continuing operations
29 896
29 539
4 636
4 601
245
112
34 777
34 252
Selling, general and administration
– 11 657
– 11 617
– 2 076
– 2 218
– 464
– 534
– 14 197
– 14 369
Research and development
– 8 118
– 8 152
– 862
– 1 250
– 8 980
– 9 402
Other income
922
1 586
176
167
644
278
1 742
2 031
Other expense
– 1 871
– 2 069
– 831
– 749
– 488
– 608
– 3 190
– 3 426
Operating income from continuing operations
9 172
9 287
1 043
551
– 63
– 752
10 152
9 086
Income from associated companies
1
1
2
2
670
656
673
659
Interest expense
– 869
– 850
Other financial income and expense
– 78
45
Income before taxes from continuing operations
9 878
8 940
Taxes
– 1 807
– 1 793
Net income from continuing operations
8 071
7 147
Net loss from discontinued operations before gain on

distribution of Alcon Inc. to Novartis AG shareholders
















– 101
Gain on distribution of Alcon Inc. to Novartis AG shareholders
4 691
Net income from discontinued operations
4 590
Net income
8 071
11 737
Attributable to:
Shareholders of Novartis AG
8 072
11 732
Non-controlling interests
– 1
5
Included in net income from continuing operations are:
Interest income
91
245
Depreciation of property, plant and equipment
– 912
– 952
– 282
– 283
– 124
– 110
– 1 318
– 1 345
Depreciation of right-of-use assets
– 273
– 247
– 41
– 41
– 16
– 17
– 330
– 305
Amortization of intangible assets
– 3 080
– 2 509
– 370
– 315
– 12
– 12
– 3 462
– 2 836
Impairment charges on property, plant and equipment, net
– 324
– 100
– 116
– 101
– 1
– 440
– 202
Impairment charges on intangible assets, net
– 768
– 632
– 141
– 506
– 5
– 914
– 1 138
Impairment charges and fair value

changes on financial assets, net


153


18






182


20


335


38
Additions to restructuring provisions
– 217
– 229
– 98
– 165
– 39
– 98
– 354
– 492
Equity-based compensation of Novartis equity plans
– 714
– 761
– 64
– 67
– 180
– 239
– 958
– 1 067
 
 
 
Innovative Medicines
Sandoz
Corporate (including eliminations)
Group
(USD millions)
2019
2018
2019
2018
2019
2018
2019
2018
Net sales to third parties from continuing operations
37 714
34 892
9 731
9 859
47 445
44 751
Sales to continuing and discontinued segments
783
741
141
177
– 871
– 836
53
82
Net sales from continuing operations
38 497
35 633
9 872
10 036
– 871
– 836
47 498
44 833
Other revenues
1 092
1 188
63
62
24
16
1 179
1 266
Cost of goods sold
– 10 050
– 9 870
– 5 334
– 5 530
959
890
– 14 425
– 14 510
Gross profit from continuing operations
29 539
26 951
4 601
4 568
112
70
34 252
31 589
Selling, general and administration
– 11 617
– 10 907
– 2 218
– 2 305
– 534
– 505
– 14 369
– 13 717
Research and development
– 8 152
– 7 675
– 1 250
– 814
– 9 402
– 8 489
Other income
1 586
977
167
505
278
147
2 031
1 629
Other expense
– 2 069
– 1 475
– 749
– 622
– 608
– 512
– 3 426
– 2 609
Operating income from continuing operations
9 287
7 871
551
1 332
– 752
– 800
9 086
8 403
Income from associated companies
1
1
2
5
656
6 432
659
6 438
Interest expense
– 850
– 932
Other financial income and expense
45
186
Income before taxes from continuing operations
8 940
14 095
Taxes
– 1 793
– 1 295
Net income from continuing operations
7 147
12 800
Net loss from discontinued operations before gain on

distribution of Alcon Inc. to Novartis AG shareholders














– 101


– 186
Gain on distribution of Alcon Inc. to Novartis AG shareholders
4 691
Net income/(loss) from discontinued operations
4 590
– 186
Net income
11 737
12 614
Attributable to:
Shareholders of Novartis AG
11 732
12 611
Non-controlling interests
5
3
Included in net income from continuing operations are:
Interest income
245
292
Depreciation of property, plant and equipment
– 952
– 1 075
– 283
– 285
– 110
– 122
– 1 345
– 1 482
Depreciation of right-of-use assets  1
– 247
– 41
– 17
– 305
Amortization of intangible assets
– 2 509
– 2 214
– 315
– 366
– 12
– 7
– 2 836
– 2 587
Impairment charges on property, plant and equipment, net
– 100
– 239
– 101
– 60
– 1
– 2
– 202
– 301
Impairment charges on intangible assets, net
– 632
– 592
– 506
– 249
– 1 138
– 841
Impairment charges and fair value

changes on financial assets, net


18


107






20


– 113


38


– 6
Additions to restructuring provisions
– 229
– 395
– 165
– 32
– 98
– 94
– 492
– 521
Equity-based compensation of Novartis equity plans
– 761
– 645
– 67
– 53
– 239
– 220
– 1 067
– 918
 1  Depreciation of right-of-use assets recognized from January 1, 2019, the date of implementation of IFRS 16 Leases. Note 1 provides additional disclosures.
 
Segmentation - Consolidated balance sheets
Segmentation – consolidated balance sheets
Innovative Medicines
Sandoz
Corporate (including eliminations)
Group
(USD millions)
2020
2019
2020
2019
2020
2019
2020
2019
Total assets
83 112
71 225
16 825
16 468
32 122
30 677
132 059
118 370
Total liabilities
– 15 472
– 15 332
– 3 786
– 3 804
– 56 135
– 43 683
– 75 393
– 62 819
Total equity
56 666
55 551
Net debt  1
24 481
15 938
24 481
15 938
Net operating assets
67 640
55 893
13 039
12 664
468
2 932
81 147
71 489
Included in assets and liabilities are:
Total property, plant and equipment
9 863
9 632
1 849
1 888
551
549
12 263
12 069
Additions to property, plant

and equipment  2


926


1 114


229


217


110


143


1 265


1 474
Total right-of-use assets
1 489
1 487
133
136
54
54
1 676
1 677
Additions to right-of-use assets  2
264
454
67
49
15
34
346
537
Total goodwill and intangible assets
56 839
46 336
9 817
8 892
152
83
66 808
55 311
Additions to goodwill and

intangible assets  2


1 235


647


105


68


85


52


1 425


767
Total investment in associated

companies


194


128


8


7


9 430


8 509


9 632


8 644
Additions to investment in associated

companies


24


44






7


11


31


55
Cash and cash equivalents, marketable securities,

commodities, time deposits and derivative

financial instruments




















11 563




11 446




11 563




11 446
Financial debts and derivative

financial instruments










36 044


27 384


36 044


27 384
Current income tax and deferred tax liabilities
9 880
8 061
9 880
8 061
 1  Note 29 provides additional disclosures related to net debt
 2  Excluding the impact of business acquisitions
Net sales and total of selected non-current assets, by countries and regions
Net sales1
Total of selected non-current assets2
(USD millions)
2020
%
2019
%
2018
%
2020
%
2019
%
Country
Switzerland
800
2
848
2
795
2
34 904
39
33 032
43
United States
16 484
34
16 280
34
14 618
33
39 889
44
28 893
37
France
2 442
5
2 442
5
2 505
6
4 115
5
3 933
5
Germany
4 518
9
4 120
9
3 972
9
2 607
3
2 554
3
Japan
2 804
6
2 656
6
2 575
6
313
309
China
2 573
5
2 214
5
1 953
4
714
1
684
1
Other
19 038
39
18 885
39
18 333
40
7 837
8
8 296
11
Group
48 659
100
47 445
100
44 751
100
90 379
100
77 701
100
Region
Europe
18 715
38
17 933
38
17 259
39
47 798
53
46 103
59
Americas
19 725
41
19 713
41
18 032
39
40 391
45
29 389
38
Asia/Africa/Australasia
10 219
21
9 799
21
9 460
22
2 190
2
2 209
3
Group
48 659
100
47 445
100
44 751
100
90 379
100
77 701
100
 
 1  Net sales to third party from continuing operations by location of customer
 2  Total of property, plant and equipment; right-of-use assets; goodwill; intangible assets and investment in associated companies
Net sales by region
Segmentation – Net sales by region 1




2020

USD m




2019

USD m
Change

(2019

to 2020)

USD %




2018

USD m
Change

(2018

to 2019)

USD %
Innovative Medicines
Europe
13 484
12 818
5
12 296
4
US
14 342
13 789
4
11 864
16
Asia/Africa/Australasia
8 718
8 458
3
8 097
4
Canada and Latin America
2 469
2 649
– 7
2 635
1
Total
39 013
37 714
3
34 892
8
Of which in Established Markets
29 643
28 573
4
26 258
9
Of which in Emerging Growth Markets
9 370
9 141
3
8 634
6
Sandoz
Europe
5 231
5 115
2
4 963
3
US
2 142
2 491
– 14
2 754
– 10
Asia/Africa/Australasia
1 501
1 341
12
1 363
– 2
Canada and Latin America
772
784
– 2
779
1
Total
9 646
9 731
– 1
9 859
– 1
Of which in Established Markets
7 089
7 111
0
7 233
– 2
Of which in Emerging Growth Markets
2 557
2 620
– 2
2 626
0
Group
Europe
18 715
17 933
4
17 259
4
US
16 484
16 280
1
14 618
11
Asia/Africa/Australasia
10 219
9 799
4
9 460
4
Canada and Latin America
3 241
3 433
– 6
3 414
1
Total
48 659
47 445
3
44 751
6
Of which in Established Markets
36 732
35 684
3
33 491
7
Of which in Emerging Growth Markets
11 927
11 761
1
11 260
4
 1  Net sales to third parties from continuing operations by location of customer. Emerging Growth Markets comprise all markets other than the Established Markets of the US, Canada, Western Europe, Japan, Australia and New Zealand.
 
Other revenue
Segmentation – other revenue
Innovative Medicines
Sandoz
Corporate (including eliminations)
Group
(USD millions)
2020
2019
2020
2019
2020
2019
2020
2019
Profit-sharing income
835
732
2
835
734
Royalty income
107
104
25
19
168
24
300
147
Milestone income
39
201
11
30
50
231
Other  1
37
55
17
12
54
67
Total other revenues
1 018
1 092
53
63
168
24
1 239
1 179
 1  Other includes revenue from activities such as manufacturing or other services rendered, to the extent such revenue is not recorded under net sales.
Innovative Medicines
Sandoz
Corporate (including eliminations)
Group
(USD millions)
2019
2018
2019
2018
2019
2018
2019
2018
Profit-sharing income
732
874
2
3
734
877
Royalty income
104
162
19
10
24
16
147
188
Milestone income
201
128
30
45
231
173
Other  1
55
24
12
4
67
28
Total other revenues
1 092
1 188
63
62
24
16
1 179
1 266
 1  Other includes revenue from activities such as manufacturing or other services rendered, to the extent such revenue is not recorded under net sales.
Innovative Medicines  
Statement [line items]  
Net sales by business franchise
Innovative Medicines Division net sales by business franchise




2020

USD m




2019

USD m
Change

(2019 to

2020)

USD %




2018

USD m
Change

(2018 to

2019)

USD %
Oncology
Tasigna
1 958
1 880
4
1 874
0
Promacta/Revolade
1 738
1 416
23
1 174
21
Tafinlar + Mekinist
1 542
1 338
15
1 155
16
Sandostatin
1 439
1 585
– 9
1 587
0
Jakavi
1 339
1 114
20
977
14
Gleevec/Glivec
1 188
1 263
– 6
1 561
– 19
Afinitor/Votubia
1 083
1 539
– 30
1 556
– 1
Kisqali
687
480
43
235
104
Exjade/Jadenu
653
975
– 33
1 099
– 11
Votrient
635
755
– 16
828
– 9
Kymriah
474
278
71
76
nm
Lutathera
445
441
1
167
164
Piqray
320
116
176
nm
Adakveo
105
1
nm
nm
Tabrecta
35
nm
nm
Other
1 070
1 189
– 10
1 139
4
Total Novartis Oncology business unit
14 711
14 370
2
13 428
7
Immunology, Hepatology and Dermatology
Cosentyx
3 995
3 551
13
2 837
25
Ilaris
873
671
30
554
21
Other
1
nm
Total Immunology, Hepatology and Dermatology
4 868
4 222
15
3 392
24
Ophthalmology
Lucentis
1 933
2 086
– 7
2 046
2
Xiidra
376
192
96
nm
Beovu
190
35
nm
nm
Other
1 911
2 463
– 22
1 995
23
Total Ophthalmology
4 410
4 776
– 8
4 558
5
Neuroscience
Gilenya
3 003
3 223
– 7
3 341
– 4
Zolgensma
920
361
155
nm
Mayzent
170
26
nm
nm
Aimovig
164
103
59
8
nm
Kesimpta
15
nm
nm
Other
51
60
– 15
80
– 25
Total Neuroscience
4 323
3 773
15
3 429
10




2020

USD m




2019

USD m
Change

(2019 to

2020)

USD %




2018

USD m
Change

(2018 to

2019)

USD %
Cardiovascular, Renal and Metabolism
Entresto
2 497
1 726
45
1 028
68
Other
1
24
– 96
22
9
Total Cardiovascular, Renal and Metabolism
2 498
1 750
43
1 050
67
Respiratory
Xolair  1
1 251
1 173
7
1 039
13
Ultibro Group
623
630
– 1
703
– 10
Other
26
22
18
25
– 12
Total Respiratory
1 900
1 825
4
1 767
3
Established Medicines
Galvus Group
1 199
1 297
– 8
1 284
1
Diovan Group
1 003
1 064
– 6
1 023
4
Exforge Group
980
1 025
– 4
1 002
2
Zortress/Certican
452
485
– 7
464
5
Neoral/Sandimmun(e)
393
419
– 6
463
– 10
Voltaren/Cataflam
360
417
– 14
445
– 6
Other
1 916
2 291
– 16
2 587
– 11
Total Established Medicines
6 303
6 998
– 10
7 268
– 4
Total Novartis Pharmaceuticals business unit
24 302
23 344
4
21 464
9
Total division net sales
39 013
37 714
3
34 892
8
 1  Net sales reflect Xolair sales for all indications.
 
nm = not meaningful
Net sales of Top 20 products
Top 20 Innovative Medicines Division product net sales – 2020


Brands




Business franchise




Key indication


US

USD m
Rest of

world

USD m


Total

USD m


Cosentyx






Immunology, Hepatology

and Dermatology
Psoriasis, ankylosing

spondylitis, psoriatic

arthritis and

non-radiographic axial

spondyloarthritis








2 516








1 479








3 995
Gilenya
Neuroscience
Relapsing multiple sclerosis
1 562
1 441
3 003


Entresto
Cardiovascular, Renal

and Metabolism


Chronic heart failure


1 277


1 220


2 497
Tasigna
Oncology
Chronic myeloid leukemia
859
1 099
1 958
Lucentis
Ophthalmology
Age-related macular degeneration
1 933
1 933


Promacta/Revolade


Oncology
Immune thrombocytopenia (ITP),

severe aplastic anemia (SAA)


833


905


1 738


Tafinlar + Mekinist




Oncology
BRAF V600+ metastatic and

adjuvant melanoma; advanced

non-small cell lung cancer (NSCLC)




569




973




1 542
Sandostatin
Oncology
Carcinoid tumors and acromegaly
837
602
1 439


Jakavi


Oncology
Myelofibrosis (MF),

polycythemia vera (PV)




1 339


1 339


Xolair  1




Respiratory
Severe allergic asthma (SAA)

and chronic spontaneous urticaria

(CSU) and nasal polyps








1 251




1 251
Galvus Group
Established Medicines
Type 2 diabetes
1 199
1 199
Gleevec/Glivec
Oncology
Chronic myeloid leukemia and GIST
315
873
1 188
Afinitor/Votubia
Oncology
Breast cancer/TSC
644
439
1 083
Diovan Group
Established Medicines
Hypertension
124
879
1 003
Exforge Group
Established Medicines
Hypertension
16
964
980
Zolgensma
Neuroscience
Spinal muscular atrophy (SMA)
459
461
920


Ilaris


Immunology, Hepatology

and Dermatology
Auto-inflammatory (CAPS,

TRAPS, HIDS/MKD, FMF, SJIA,

AOSD and gout)




400




473




873
Kisqali
Oncology
HR+/HER2- metastatic breast cancer
318
369
687
Exjade/Jadenu
Oncology
Chronic iron overload
138
515
653
Votrient
Oncology
Renal cell carcinoma
259
376
635
Top 20 products total
11 126
18 790
29 916
Rest of portfolio
3 216
5 881
9 097
Total division sales
14 342
24 671
39 013
 1  Net sales reflect Xolair sales for all indications.
Top 20 Innovative Medicines Division product net sales – 2019


Brands




Business franchise




Key indication


US

USD m
Rest of

world

USD m


Total

USD m


Cosentyx
Immunology, Hepatology

and Dermatology
Psoriasis, ankylosing

spondylitis and psoriatic arthritis


2 220


1 331


3 551
Gilenya
Neuroscience
Relapsing multiple sclerosis
1 736
1 487
3 223
Lucentis
Ophthalmology
Age-related macular degeneration
2 086
2 086
Tasigna
Oncology
Chronic myeloid leukemia
804
1 076
1 880


Entresto
Cardiovascular, Renal

and Metabolism


Chronic heart failure


925


801


1 726
Sandostatin
Oncology
Carcinoid tumors and acromegaly
881
704
1 585
Afinitor/Votubia
Oncology
Breast cancer/TSC
1 003
536
1 539


Promacta/Revolade


Oncology
Immune thrombocytopenia (ITP),

severe aplastic anemia (SAA)


691


725


1 416


Tafinlar + Mekinist




Oncology
BRAF V600+ metastatic and

adjuvant melanoma; advanced

non-small cell lung cancer (NSCLC)




481




857




1 338
Galvus Group
Established Medicines
Type 2 diabetes
1 297
1 297
Gleevec/Glivec
Oncology
Chronic myeloid leukemia and GIST
334
929
1 263


Xolair  1




Respiratory
Severe allergic asthma (SAA)

and chronic spontaneous urticaria

(CSU)








1 173




1 173


Jakavi


Oncology
Myelofibrosis (MF),

polycythemia vera (PV)




1 114


1 114
Diovan Group
Established Medicines
Hypertension
86
978
1 064
Exforge Group
Established Medicines
Hypertension
13
1 012
1 025
Exjade/Jadenu
Oncology
Chronic iron overload
450
525
975
Votrient
Oncology
Renal cell carcinoma
332
423
755


Ilaris


Immunology, Hepatology

and Dermatology
Auto-inflammatory (CAPS,

TRAPS, HIDS/MKD, FMF, SJIA,

AOSD and gout)




304




367




671
Zortress/Certican
Established Medicines
Transplantation
169
316
485
Kisqali
Oncology
HR+/HER2- metastatic breast cancer
250
230
480
Top 20 products total
10 679
17 967
28 646
Rest of portfolio
3 110
5 958
9 068
Total division sales
13 789
23 925
37 714
 1  Net sales reflect Xolair sales for all indications.
 
Top 20 Innovative Medicines Division product net sales – 2018


Brands




Business franchise




Key indication


US

USD m
Rest of

world

USD m


Total

USD m
Gilenya
Neuroscience
Relapsing multiple sclerosis
1 765
1 576
3 341


Cosentyx
Immunology, Hepatology

and Dermatology
Psoriasis, ankylosing

spondylitis and psoriatic arthritis


1 674


1 163


2 837
Lucentis
Ophthalmology
Age-related macular degeneration
2 046
2 046
Tasigna
Oncology
Chronic myeloid leukemia
806
1 068
1 874
Sandostatin
Oncology
Carcinoid tumors and acromegaly
817
770
1 587
Gleevec/Glivec
Oncology
Chronic myeloid leukemia and GIST
440
1 121
1 561
Afinitor/Votubia
Oncology
Breast cancer/TSC
929
627
1 556
Galvus Group
Established Medicines
Type 2 diabetes
1 284
1 284


Promacta/Revolade


Oncology
Immune thrombocytopenia (ITP),

severe aplastic anemia (SAA)


581


593


1 174


Tafinlar + Mekinist




Oncology
BRAF V600+ metastatic and

adjuvant melanoma; advanced

non-small cell lung cancer (NSCLC)




457




698




1 155
Exjade/Jadenu
Oncology
Chronic iron overload
521
578
1 099


Xolair  1




Respiratory
Severe allergic asthma (SAA)

and chronic spontaneous urticaria

(CSU)








1 039




1 039


Entresto
Cardiovascular, Renal

and Metabolism


Chronic heart failure


556


472


1 028
Diovan Group
Established Medicines
Hypertension
84
939
1 023
Exforge Group
Established Medicines
Hypertension
19
983
1 002


Jakavi


Oncology
Myelofibrosis (MF),

polycythemia vera (PV)




977


977
Votrient
Oncology
Renal cell carcinoma
404
424
828


Ilaris


Immunology, Hepatology

and Dermatology
Auto-inflammatory (CAPS,

TRAPS, HIDS/MKD, FMF, SJIA,

AOSD and gout)




262




292




554


Travoprost Group


Ophthalmology
Reduction of elevated intraocular

pressure


194


323


517
Zortress/Certican
Established Medicines
Transplantation
145
319
464
Top 20 products total
9 654
17 292
26 946
Rest of portfolio
2 210
5 736
7 946
Total division sales
11 864
23 028
34 892
 1  Net sales reflect Xolair sales for all indications.
 
Sandoz [member]  
Statement [line items]  
Net sales by business franchise
Sandoz Division net sales by business franchise




2020

USD m




2019

USD m
Change

(2019 to

2020)

USD %




2018

USD m
Change

(2018 to

2019)

USD %
Retail Generics  1
7 244
7 590
– 5
7 880
– 4
Biopharmaceuticals
1 928
1 607
20
1 436
12
Anti-Infectives
474
534
– 11
543
– 2
Total division net sales
9 646
9 731
– 1
9 859
– 1
 1  Of which USD 694 million (2019: USD 784 million; 2018: USD 826 million) represents anti-infectives sold under the Sandoz name